Clinical Decision Support System for Quality Assurance in Potassium-Increasing Drug-Drug-Interactions
Status
Conditions
Treatments
Details and patient eligibility
About
To investigate the impact of reminders for serum potassium monitoring and of hyperkalemia alerts during potassium-increasing drug-drug-interactions.
Full description
The development of hyperkalemia during potassium-increasing drug-drug-interactions (DDIs) is associated with (i) unknown or elevated serum potassium level at onset of treatment and (ii) insufficient monitoring of serum potassium during therapy. However, potassium-increasing DDIs are frequently started despite an unknown or elevated serum potassium level, and monitoring intervals often exceed 48 hours.
This study investigates the impact of reminders for serum potassium monitoring and hyperkalemia alerts. Both reminders and alerts are displayed in the electronic patient chart of in-patients treated with potassium-increasing DDIs.
Enrollment
Sex
Volunteers
Inclusion criteria
- in-patients treated with concurrent potassium-increasing drugs
Exclusion criteria
- outpatients; in-patients on wards without computerized physician order entry (i.e. patients treated in the ICU)
Trial design
Primary purpose
Allocation
Interventional model
Masking
3,341 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal